novo nordisk semaglutide nash FDA Approval Expands Nordisk's Wegovy to the Fatty Liver Disease MASH Novo Nordisk will file semaglutide

Physical therapy units commonly wrong

SURMOUNT-1 Trial (Tirzepatide, N=2,539) Tirzepatide, a dual GIP and GLP-1 receptor agonist, produced a similar GI side-effect profile

A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease

This enhanced vascularization delivers more healing resources to the injury site while also improving waste removal from damaged areas

A healthy body produces enough alpha-lipoic acid endogenously to supply its requirements as an enzyme cofactor